FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum‐Containing Chemotherapy

On August 5, 2016, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA injection, Merck Sharp & Dohme Corp., Kenilworth, NJ) for treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on...

Descripción completa

Detalles Bibliográficos
Autores principales: Larkins, Erin, Blumenthal, Gideon M., Yuan, Weishi, He, Kun, Sridhara, Rajeshwari, Subramaniam, Sriram, Zhao, Hong, Liu, Chao, Yu, Jingyu, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Regulatory Issues: FDA
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507654/
https://www.ncbi.nlm.nih.gov/pubmed/28533473
http://dx.doi.org/10.1634/theoncologist.2016-0496

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507654/
https://www.ncbi.nlm.nih.gov/pubmed/28533473
http://dx.doi.org/10.1634/theoncologist.2016-0496

Ejemplares similares